(Solid Tumors) Is ATR Inhibitor Ceralasertib Effective?

Formerly certified by Japan's Ministry of Foreign Affairs and METI as an international medical visa guarantor (B-066).

(Solid Tumors) Is ATR Inhibitor Ceralasertib Effective?

• September 23, 2021
• 2 min read

During the ESMO Congress 2021 (September 23–26), Rahul Aggarwal and his team from the University of California, San Francisco (UCSF) presented experimental results on the efficacy and safety of Ceralasertib, an oral ATR inhibitor, used alone or in combination with Lynparza (olaparib) for patients with ARID1A-deficient advanced solid tumors.

In this trial, patients with ARID1A-deficient advanced solid tumors were divided into two cohorts: Cohort 1: Ceralasertib monotherapy (160 mg twice daily on days 1–14 of a 28-day cycle; N=10). Cohort 2: Ceralasertib plus Lynparza combination therapy (Ceralasertib 160 mg twice daily on days 1–7 and Lynparza 300 mg twice daily on days 1–28 of a 28-day cycle; N=10). The primary endpoint was the objective response rate (ORR).

The results showed that in Cohort 1 (monotherapy), the ORR was 20%, with 2 patients achieving a complete response (CR). These patients remained in CR for over 21.3 months and 16.3 months, respectively.

In Cohort 2 (combination therapy), the best response observed was stable disease (SD), which was achieved by 4 out of 10 patients. No objective responses were observed in this cohort.

Regarding safety, Grade 3 or higher adverse events included thrombocytopenia (10%) and neutropenia (20%), both of which were manageable through temporary treatment interruption or dose reduction.

Based on these results, Rahul Aggarwal and colleagues concluded that Ceralasertib monotherapy shows promising anti-tumor activity and durable responses in patients with ARID1A-deficient advanced solid tumors.

Source: https://www.esmo.org/oncology-news/antitumour-activity-of-ceralasertib-in-arid1a-deficient-solid-tumours

#SolidTumors #ATRInhibitor #Ceralasertib #ARID1A #Lynparza #ESMO2021 #CancerResearch

Figure 1

Figure 2

Figure 3

Figure 4